Oxford Biomedica PLC Repayment of Debt Facility (7435D)
28 June 2019 - 4:01PM
UK Regulatory
TIDMOXB
RNS Number : 7435D
Oxford Biomedica PLC
28 June 2019
Oxford Biomedica
Repayment of Debt Facility
Oxford, UK - 28 June 2019: Oxford Biomedica plc (LSE:OXB) ("OXB"
or "the Group"), a leading gene and cell therapy group, announces
that, further to the announcement of 28 May in relation to Novo
Holdings' strategic investment in the Group and, in accordance with
the stated use of proceeds from the transaction, Oxford Biomedica
has now repaid in full its debt facility with Oaktree Capital
Management.
-Ends-
Enquiries:
Oxford Biomedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Catherine Isted, Head of Corporate T: +44 (0)1865 783 000
Development & IR T: +44 (0)1865 783 000
Sarah MacLeod, Head of Communications T: +44 (0)1865 954 161 / E: ir@oxb.com
T: +44 (0)7747 602 739 / E: media@oxb.com
T: +44 (0)20 3709 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford Biomedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, Axovant Gene
Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK
Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations,
through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford Biomedica is based
across several locations in Oxfordshire, UK and employs more than
430 people. Further information is available at www.oxb.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCDDGDLLDDBGCR
(END) Dow Jones Newswires
June 28, 2019 02:01 ET (06:01 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024